Goodpasture's syndrome treated with mycophenolate mofetil

Garcia-Canton, C.; Toledo, A.; Palomar, Rosa; F, Fernández Martínez; López, Juliette Suárez; Moreno, Adriana S.; Esparza, Noemí; Suria, S.; Rossique, P.; Díaz, Joan Manuel; Checa, D.

doi:10.1093/ndt/15.6.920

Cited by 32 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all patients, remission was achieved, with only one relapse after 14 mo. Successful MMF treatment of IgA nephritis and Goodpasture syndrome has also been reported in anecdotal form (26,58). In the study by Choi and co-workers (11), patients with membranoproliferative glomerulonephritis and IgA nephropathy also experienced improvement with MMF treatment.…”

Section: Beneficial Effects Of Mmf In Immunemediated Nephropathiesmentioning

confidence: 93%

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies

Zatz

Noronha

Fujihara

2002

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

The incidence of progressive nephropathies and, consequently, the population suffering from end-stage renal disease have increased steadily in recent years, posing an ever-growing cost, in both human and financial terms, to society. There is mounting evidence that, in both immune-mediated and nonimmune-mediated chronic nephropathies, renal inflammatory events are key to the propagation and perpetuation of renal injury. Mycophenolate mofetil (MMF) is an antilymphocyte agent recently introduced in clinical practice for the prevention of allograft rejection. The present review discusses clinical and experimental evidence that the anti-inflammatory action of MMF can be advantageously used to arrest immune- and nonimmune-mediated progressive injury of native kidneys as well.

show abstract

Section: Beneficial Effects Of Mmf In Immunemediated Nephropathiesmentioning

confidence: 93%

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies

Zatz

Noronha

Fujihara

2002

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

show abstract

“…There are no clinical trials for the treatment in GS, but rituximab and mycophenolate mofetil are also reported as treatments. 3,12 In conclusion, GS should be considered in young men with hemoptysis, particularly those who smoke. Invasive procedures such as bronchoscopy should be avoided as much as possible in making a diagnosis.…”

Section: Discussionmentioning

confidence: 98%

What triggered massive hemoptysis in Goodpasture syndrome with isolated pulmonary involvement in a 14-year-old boy?

et al. 2019

View full text Add to dashboard Cite

Şişmanlar-Eyüboğlu T, Aslan AT, Gezgin-Yıldırım D, Buyan N, Emeksiz S, Kalkan G. What triggered massive hemoptysis in Goodpasture syndrome with isolated pulmonary involvement in a 14-year-old boy? Turk J Pediatr 2019; 61: 611-614.Goodpasture syndrome is a rare, autoimmune disease associated with the development of antibodies against a specific antigen both in glomerular basement membrane and alveolar basement membrane. It is very rare in childhood and its incidence is not known. Although the mechanism of the disease is the same in lung as in the kidney, sometimes it presents with involvement of only one organ. Pulmonary involvement may be lifethreatening in patients with massive hemoptysis. Herein we report a 14-yearold boy with isolated lung involvement. He had massive hemoptysis following bronchoscopy and recovered succesfully with treatment.

show abstract

“…Alternatively, immunoadsorption with protein A has been used in substitution for plasmapheresis [16,17]. Also, mycophenolate mofetil was administered with success to one patient with frequent relapses of lung hemorrhage, utilizing the normal dosage [18].…”

Section: Discussionmentioning

confidence: 99%

Anti-glomerular basement membrane glomerulonephritis in an HIV positive patient: case report

Monteiro¹,

Caron²,

Balda³

et al. 2006

Braz J Infect Dis

View full text Add to dashboard Cite

We report on a case of a patient with HIV infection, diagnosed 18 months prior to the development of an anti-glomerular basement membrane (anti-GBM) rapidly progressive glomerulonephritis; this is probably the first report of such an association. A 30-year-old white man presented with elevation of serum creatinine (1.3 -13.5 mg/dL within one month). At admission, the urinalysis showed proteinuria of 7.2 g/L and 8,000,000 erythrocytes/mL. Renal biopsy corresponded to a crescentic diffuse proliferative glomerulonephritis mediated by anti-GBM, and serum testing for anti-GBM antibodies was positive; antinuclear antibodies (ANA) and anti-neutrophilic cytoplasmic antibodies (ANCA) were also positive. The patient underwent hemodyalisis and was treated with plasmapheresis, cyclophosphamide and prednisone. The association described here is not casual, as crescentic glomerulonephritis is not common in HIV-positive patients, anti-GBM glomerulonephritis is rare and anti-GBM antibodies are frequently observed in HIV-positive subjects when compared to the overall population. Based on the current case and on the elevated frequency of the positivity for such antibodies in this group of patients, it is advisable to be aware of the eventual association between these two conditions and to promote an active search for anti-GBM antibodies and early diagnosis of eventual urinary abnormalities in HIV-positive subjects, considering the severity of anti-GBM glomerulonephritis.

show abstract

Goodpasture's syndrome treated with mycophenolate mofetil

Cited by 32 publications

References 7 publications

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies

Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies

What triggered massive hemoptysis in Goodpasture syndrome with isolated pulmonary involvement in a 14-year-old boy?

Anti-glomerular basement membrane glomerulonephritis in an HIV positive patient: case report

Contact Info

Product

Resources

About